Onkológia 1/2022

Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma

Classical Hodgkin lymphoma (cHL) is a B cell-derived lymphoid malignancy most often affecting young adults. More than 80% of HL patients achieve long-term remission after appropriate first-line treatment consisting of multiagent chemotherapy and/or radiotherapy. In addition, approximately 50% of patients with disease recurrence remain relapse-free after salvage therapy with high-dose chemotherapy followed by autologous stem cell transplantation. However, patients with multiple relapses are mostly in a palliative situation, and novel drugs for this patient group are needed. The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/ refractory patients. This article will review the evolution of BV in classical Hodgkin lymphoma.

Keywords: brentuximab vedotin, Hodgkin’s lymphoma, treatment